Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Anna C. Ferreira
Observed name:
A Ferreira
Institutions:
Medical University of South Carolina,
MUSC Hollings Cancer Center
Observed institutions:
Medical University of South Carolina,
MUSC Hollings Cancer Center,
IPO Porto
ORCID:
0000-0001-5683-3923
Observed ORCID:
0000-0001-5683-3923
OpenAlex ID:
A5109337885
Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia
2025
·
Inna M. Chen
, Julia S. Johansen
, et al.
·
Journal of Clinical Oncology
·
44
PDF
Erratum: Randomized Phase II Study of Nab-Paclitaxel and Gemcitabine With or Without Tocilizumab as First-Line Treatment in Advanced Pancreatic Cancer: Survival and Cachexia
2025
·
Inna M. Chen
, Julia S. Johansen
, et al.
·
Journal of Clinical Oncology
·
7
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma after frontline DA-EPOCH-R
2025
·
Brian Hess
, Alison Moskowitz
, et al.
·
Haematologica
·
3
PDF
Risk biomarkers of chronic GVHD in children aged 10 years or younger and children/adults older than 10 years
2025
·
Anna C. Ferreira
, Debjani Dutta
, et al.
·
Blood Advances
·
2
PDF
Abstract P1-15-19: Carboplatin-addition in neoadjuvant treatment of women with triple negative breast cancer (TNBC): Prognostic value in real-world patients
2019
·
S Coelho
, MH Abreu
, et al.
·
Cancer Research
Show more works
View as search
Works count:
5
Citation count:
56
H-index:
3
I10-index:
1
Year
Topic
Type